Clinical Trial Update: Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides [Phase 1]

View source ↗

Summary

A multicentre Phase I trial from the University of Cologne evaluates engineered CD30-targeted T cells for relapsed or refractory primary cutaneous CD30+ large T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Cd30 Large T-cell Lymphoma
• Mycosis Fungoides
• Transformed Mycosis Fungoides

Drugs mentioned

• Engineered CD30-targeted T cells (CAR-T) (CD30 CAR-T cells)

Snippet

Sponsor: University of Cologne | Conditions: CD30 Positive Cutaneous T Cell Lymphoma, CD30 Positive Transformed Mycosis Fungoides | Phase 1 | Status: UNKNOWN